Trials / Completed
CompletedNCT01369784
Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
Observational, Post-authorization, Cross-sectional Study to Evaluate the Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 158 (actual)
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the prognostic value of clinical and biological factors in patients with refractory/relapsed Diffuse Large B-Cell Lymphoma.
Detailed description
The main aim of this study is to compare the prognostic value of R-IPI at diagnosis and relapse, relating it with the obtained response after second line
Conditions
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2011-06-09
- Last updated
- 2016-04-18
- Results posted
- 2016-04-18
Locations
56 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01369784. Inclusion in this directory is not an endorsement.